Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brecan Trial: Neoadjuvant PLD and Nab-Paclitaxel for HER2+ Breast Cancer
NCT05346107Phase 2Unknown
- Sponsor
- Xijing Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, paclitaxel in HER2-positive breast cancer, sponsored by Xijing Hospital. Status: unknown.
02
Drugs
pegylated liposomal doxorubicinpaclitaxel
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05346107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346107.